Gastric Tolerance of High-Dose Pulse Oral Prednisone in Multiple Sclerosis
Neurol 53:2093-2096, Metz,L.M.,et al, 1999
Quantitative MRI in CADASIL, Correlation with Disability and Cognitive Performance
Neurol 52:1361-1367, Dichgans,M.,et al, 1999
Fibromyalgia Syndrome a Decade Later
Arch Int Med 159:777-785, Goldenberg,D.L., 1999
Clinicopath Conf,Wegener's Granulomatosis with Pachymeningeal Granulomatous Inflammation, Case 9-1999
NEJM 340:945-953, , 1999
Interferon-alpha 2a Reduces MRI Disease Activity in Relapsing-Remitting Multiple Sclerosis
Neurol 52:1049-1056, Myhr,K.M.,et al, 1999
Multiple Sclerosis Associated with Uveitis in Two Large Clinic-Based Series
Neurol 52:179-181, Biousse,V.,et al, 1999
Magnetic Resonance Imaging-Based Volumetry Differentiates Idiopathic Parkinson's Syndrome from Multiple System Atrophy and Progressive Supranuclear Palsy
Ann Neurol 45:65-74, Schulz,J.B.,et al, 1999
Magnetization Transfer Imaging of Patients with Definite MS and Negative Conventional MRI
Neurol 52:845-848, Filippi,M.,et al, 1999
Primary and Transitional Progressive MS,A Clinical and MRI Cross-Sectional Study
Neurol 52:839-845, Stevenson,V.L.,et al, 1999
Development of Hypointense Lesions on T1-Weighted Spin-Echo Magnetic Resonance Images in Multiple Sclerosis,Relation to Inflammatory Activity
Arch Neurol 56:345-351, van Walderveen,M.A.A.,et al, 1999
Brain Structure and Neurocognitive and Behavioural Function in Adolescents Who Were Born Very Preterm
Lancet 353:1653-1657, Stewart,A.L.,et al, 1999
Relevance of Hypointense Lesions on Fast Fluid-Attenuated Inversion Recovery MR Images as a Marker of Disease Severity in Cases of Multiple Sclerosis
AJNR 20:813-820, Rovaris,M.,et al, 1999
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
The Relationship of MS to Physical Trauma and Psychological Stress, Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 52:1737-1745, Goodin,D.S.,et al, 1999
Trigeminal Neuralgia Triggered by Auditory Stimuli in Multiple Sclerosis
Arch Neurol 56:731-733, Hartmann,M.,et al, 1999
Ibuprofen Treatment Versus Gradual Introduction of Interferon B-1b in patients with MS
Neurol 52:1893-1895, Rice,G.P.A.,et al, 1999
Cavernous Haemangioma Mimicking Multiple Sclerosis
BMJ 318:1604-1605, Cader,M.Z.&Winer,J.B., 1999
Cerebrospinal Fluid Findings in CADASIL
Neurol 53:233, Dichgans,M.,et al, 1999
Lamotrigine Adjunctive Therapy in painful Phenomena in MS:Preliminary Observations
Neurol 53:433, Cianchetti,C.,et al, 1999
Encephalitis after Hepatitis B Vaccination, Recurrent Disseminated Encephalitis or MS?
Neurol 53:396-401, Tourbah,A.,et al, 1999
Chlamydia Pneumoniae Infection of the Central Nervous System in Multiple Sclerosis
Ann Neurol 46:6-14,4, Sriram,S.,et al, 1999
A Longitudinal Study of Brain Atrophy in Relapsing Multiple Sclerosis
Neurol 53:139-148, Simon,J.H.,et al, 1999
Multiple Sclerosis in Children Under 6 Years of Age
Neurol 53:478-484, Ruggieri,M.,et al, 1999
Benign Multiple Sclerosis? Clinical Course, Long Term Follow Up, and Assessment of Prognostic Factors
JNNP 67:148-152,138, Hawkins,S.A.&McDonnell,G.V., 1999
Magnetic Resonance Imaging Results of the PRISMS Trial:A Randomized, Double-Blind, Placebo-Controlled Study of Interferon-B1a in Relapsing-Remitting Multiple Scleroosis
Ann Neurol 46:197-206, Li,D.K.B.,et al, 1999
Chronic Thalamic Stimulation for the Tremor of Multiple Sclerosis
Neurol 53:625-628, Montgomery,E.B.,et al, 1999
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
TI-201 SPECT in Pseudotumoral Multiple Sclerosis
Clin Nucl Med 24:186-188, Obach,V.,et al, 1999
Multiple Sclerosis,Therapeutic Update
Arch Neurol 56:277-280, Tselis,A.C.&Lisak,R.P., 1999
Utilization of Unconventional Treatments by Persons with MS:Is It Alternative or Complementary?
Neurol 52:626-629, Schwartz,C.E.,et al, 1999
Neuropsychological Status in Multiple Sclerosis after Treatment with Glatiramer
Arch Neurol 56:319-324, Weinstein,A.,et al, 1999
Quantitative MRI in Patients with Clinically Isolated Syndromes Suggestive of Demyelination
Neurol 52:599-606, Sailer,M.,et al, 1999
Clinicopath Conf,Syndrome of Mitochondrial Encephalopathy,Lactic Acidosis,and Stroke-Like Episodes (MELAS),Case 39-1998
NEJM 339:1914-1923, , 1998
Clinical Approach to Inherited Peroxisomal Disorders: A Series of 27 Patients
Ann Neurol 44:720-730,713, Baumgartner,M.R.,et al, 1998
Amelioration of Flulike Symptoms at the Onset of Interferon B-1b Therapy in Multiple Sclerosis by Low-Dose Oral Steriods is Related to a Decrease in Interleukin-6 Induction
Ann Neurol 44:682-685, Martinez-Caceres,E.M.,et al, 1998
Neutralizing Antibodies to Interferon B-1a and Interferon B-1b in MS Patients are Cross-Reactive
Neurol 51:1698-1702, Khan,O.A. & Dhib-Jalbut,S., 1998
Tolterodine for Overactive Bladder
The Medical Letter 40:101-102, , 1998
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Surgical Treatment of Epilepsy in Tuberous Sclerosis,Strategies and Results in 18 Patients
Neurol 51:1263-1269, Guerreiro,M.M.,et al, 1998
The Predictive Value of CSF Ologoclonal Banding for MS 5 Years After Optic Neuritis
Neurol 51:885-887, Cole,S.R.,et al, 1998
The Phenotypic Spectrum of CADASIL:Clinical Findings in 102 Cases,
Ann Neurol 44:731-739,715, Dichgans,M.,et al, 1998
Devic's Neuromyelitis Optica:A Prospective Study of Seven Patients Treated with Prednisone and Azathioprine
Neurol 51:1219-1220, Mandler,R.N.,et al, 1998
Interferon B Therapy for Multiple Sclerosis
Lancet 352:1486-1487, Goodkin,D.E., 1998
Interferons in the Treatment of Multiple Sclerosis,Do They Prevent the Progression of the Disease?
Arch Neurol 55:1578-1580,1583, Rice,G.&Ebers,G, 1998
Interferons Should be Used to Treat Most Patients with MS
Arch Neurol 55:1581-1583, Herndon,R.M.&Jacobs,L, 1998
Randomised Double-Blind Placebo-Controlled Study of Interferon B-1a in Relapsing/Remitting Multiple Sclerosis
Lancet 352:1498-1504,1486, PRISMS, 1998
Placebo-Controlled Multicentre Randomised Trial of Interferon B-1b in Treatment of Secondary Progressive Multiple Sclerosis
Lancet 352:1491-1497,1486, European Study Group on Interferon B-1b in Seconda, 1998
Prediction of Stroke Outcome with Echoplanar Perfusion-and Diffusion-Weighted MRI
Neurol 51:418-426, Barber,P.A.,et al, 1998